Boise Cascade Announces Promotion of Chris Forrey

BOISE, Idaho--(BUSINESS WIRE)-- Boise Cascade Company (“Boise Cascade” or the “Company”) (NYSE: BCC) today announced the promotion of Chris Forrey to Vice President, Finance and Investor Relations.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240502936610/en/

Chris Forrey, Boise Cascade, Vice President, Finance & Investor Relations (Photo: Business Wire)

Chris joined Boise Cascade in 2005 and was promoted to his most recent role of Senior Finance Director in March 2022, where he has led the tax, financial reporting, accounts payable, and financial systems teams. He has also been a key contributor to the investor relations and M&A efforts for the Company.

Chris earned a master’s degree in accountancy/taxation and a bachelor’s degree in business administration in accountancy, both from Boise State University. He is a Certified Public Accountant. Chris is also actively involved in organizations that support the local community.

“Chris has a strong business intellect and curiosity that I believe will serve the Company well in his new role,” said Kelly Hibbs, SVP, CFO and Treasurer. “With this well-deserved promotion, he will take leadership of our investor relations activities. In addition, Chris will maintain oversight of his previous accountabilities, where we are fortunate to have well-established and high-performing teams in place.”

About Boise Cascade

Boise Cascade Company is one of the largest producers of engineered wood products and plywood in North America and a leading U.S. wholesale distributor of building products. For more information, visit our website at www.bc.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240502936610/en/

Investor contact: Kelly Hibbs, [email protected]
Media contact: Lisa Tschampl, [email protected]

Source: Boise Cascade Company

You May Also Be Interested In

• Fujirebio Expands Access in Canada to Blood-based Neurology Testing with Health Canada Class II Medical Device Licenses for the Lumipulse® G NfL Blood and Lumipulse G pTau 217 Plasma Assays
• Novartis remibrutinib, a high-efficacy oral BTK inhibitor, significantly reduces relapse rates and shows favorable safety profile in Phase III RMS trials
• MindMaze Therapeutics to Present at Upcoming Investor and Industry Conferences